Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Mesothelioma 1Lung Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

Docetaxel 19pembrolizumab 14Surveys and Questionnaires 7Radiotherapy 7Paclitaxel 7Magnetic Resonance Spectroscopy 7Gemcitabine 7Standard of Care 6Specimen Handling 6Radiosurgery 6Psychiatric Rehabilitation 6Early Intervention, Educational 6Trastuzumab 5Nivolumab 5enzalutamide 4Interviews as Topic 4motexafin gadolinium 3cabozantinib 3X-Rays 3Sirolimus 3Methods 3Educational Status 3Cisplatin 3Carboplatin 3Azacitidine 3tisotumab vedotin 2rucaparib 2pertuzumab 2pegilodecakin 2palbociclib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Caves × Thoracic × Clear all
NCT02769962 2025-07-28

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
45 enrolled 30 charts
GenitourinaryThoracic

Carcinoma, Transitional Cell, Lung Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡